Literature DB >> 2424596

Depression of protective mechanism during the early phase of a viral infection in tumor-bearing mice and prevention by PSK.

S Tsuru, K Nomoto, M Taniguchi, H Fujisawa, Y Zinnaka.   

Abstract

Effector mechanisms responsible for resistance against ectromelia virus including antiviral activity of non-immune macrophages, antiviral antibody, delayed footpad reaction to viral antigen, and interferon induction after viral infection were depressed in BALB/c mice bearing syngeneic Meth A tumor. The degree of viral growth correlated well with the depression of delayed footpad reaction, antibody production, and interferon induction. Therefore, modification of macrophage functions by a tumor-bearing state and treatment with PSK may contribute to this modification of antiviral resistance, at an early phase of infection. Cytotoxic activity may not be the principal effector, since the cytotoxicity was induced in normal and tumor-bearing mice to almost the same extent yet an extensive viral growth occurred only in the latter.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424596     DOI: 10.1007/bf00199124

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

1.  Restoration of antibody-forming capacities by PS-K in tumor-bearing mice.

Authors:  K Nomoto; C Yoshikumi; K Matsunaga; T Fujii; K Takeya
Journal:  Gan       Date:  1975-08

2.  Potentiation of experimental arbovirus encephalitis by immunosuppressive doses of cyclophosphamide.

Authors:  G A Cole; N Nathanson
Journal:  Nature       Date:  1968-10-26       Impact factor: 49.962

3.  Recovery from primary infection with Langat E5 virus in normal and cyclophosphamide treated mice: relative roles of virus multiplication, interferon, antibody and serum protective factor.

Authors:  I S Thind; W H Price
Journal:  Am J Epidemiol       Date:  1969-05       Impact factor: 4.897

4.  Cross-protection with group B arboviruses in mice treated with cyclophosphamide: role of serum antibody, viremia, and virus multiplication in the brain.

Authors:  I S Thind; W H Price
Journal:  Am J Epidemiol       Date:  1969-01       Impact factor: 4.897

5.  Mechanism of protection during the early phase of a generalized viral infection. I. Contribution of phagocytes to protection against ectromelia virus.

Authors:  S Tsuru; H Kitani; M Seno; M Abe; Y Zinnaka; K Nomoto
Journal:  J Gen Virol       Date:  1983-09       Impact factor: 3.891

6.  Cell-mediated cytotoxicity against ectromelia virus-infected target cells. I. Specificity and kinetics.

Authors:  I Gardner; N A Bowern; R V Blanden
Journal:  Eur J Immunol       Date:  1974-02       Impact factor: 5.532

7.  Effects of cholera toxin on the lymphoid system II. Selective augmentation of delayed footpad reaction in mice.

Authors:  S Tsuru; Y Zinnaka; K Nomoto; K Takeya
Journal:  J Clin Lab Immunol       Date:  1981-09

8.  Depression of macrophage functions and T-cell-mediated immunity to listeria infection in tumor-bearing mice and its prevention by PSK.

Authors:  S Tsuru; K Nomoto; M Taniguchi; H Kitani; M Watanabe; Y Zinnaka
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Effects of PSK on specific tumor immunity to syngeneic tumor cells.

Authors:  S Tsuru; K Nomoto
Journal:  J Clin Lab Immunol       Date:  1983-04

10.  Mouse strain difference in the expression of antitumor activity of PS-K.

Authors:  C Yoshikumi; K Nomoto; K Matsunaga; T Fuji; K Takeya
Journal:  Gan       Date:  1975-12
View more
  2 in total

Review 1.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03

2.  Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease.

Authors:  Eva Szigethy; Ada O Youk; Joseph Gonzalez-Heydrich; Simona I Bujoreanu; John Weisz; Diane Fairclough; Peter Ducharme; Neil Jones; Francis Lotrich; David Keljo; Arvind Srinath; Athos Bousvaros; David Kupfer; David R DeMaso
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.